NEWS
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
Evaxion has published Phase 1 study data for its AI-designed personalized cancer vaccine, EVX-01, in the Journal for ImmunoTherapy of Cancer. The study showed a 67% objective response rate (ORR) in patients with metastatic melanoma, with eight out of 12 patients showing clinical responses — six partial and two complete. EVX-01, co-administered with anti-PD-1 therapy, did not cause serious vaccine-related adverse events. The results validate the precision of Evaxion's AI-Immunology™ platform. Phase 2 of the EVX-01 program is underway, with 71% of administered neoantigens inducing specific T-cell responses, as presented at ASCO. The one-year efficacy readout is expected in Q3 2024. CEO Christian Kanstrup expressed optimism about these promising results.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1029Followers
64Following
6959Visitors
Follow
OneNightOnly : Bro, how did u always manage to get these news so fast?